Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been...
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
SAGE Publishing
2020-06-01
|
| Reeks: | Therapeutic Advances in Neurological Disorders |
| Online toegang: | https://doi.org/10.1177/1756286420932035 |